Rezūm water vapour thermal therapy for benign prostatic hyperplasia: early results from the United Kingdom
BAUS ePoster online library. Johnston M. 06/27/18; 211363; P8-2 Disclosure(s)(s): Educational grant received from Kebomed UK.
Mr. Maximilian Johnston
Mr. Maximilian Johnston
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
Introduction: The Rezūm System is a novel minimally invasive thermal therapy for the treatment of symptomatic BPH. We evaluated this new transurethral therapy in patients with moderate to severe symptoms.

Materials & Methods: Ongoing prospective registry evaluation of the first 67 consecutive cases performed in the UK at two centres. All patients had moderate or severe symptoms. Prostate volumes ranged from 22-110mls; patients with an obstructing median lobe and those in retention were included. Pre- and post-procedure assessments included the IPSS questionnaire with quality of life (QOL), urinary flow rate (Qmax), prostate volume and indwelling catheter presence.

Results: 36 of 67 procedures were performed under local anaesthetic with sedation. At 3 months, mean IPSS was significantly improved (-13.1 points)(p<0.001) as was IPSS-QOL (p<0.001). Qmax improved by 6mL/s at 4-6 weeks, 8.4mL/s at 3 months, p<0.001 and 8.8ml/s at 6 months, p=0.002.. Prostate volume was reduced by 36% at 3 months, p=0.002. After first trial without catheter, 56/67 (84%) were successful; at 3 months 65/67 (97%) were catheter free. Using the Clavien-Dindo system there were two grade II complications (UTI requiring antibiotics), three grade 3b (two patients returned to theatre for clot retention 1 month post operatively, and one had transurethral resection of infected prostate tissue at 3 weeks).

Conclusions: Preliminary results of this UK experience with the Rezūm procedure demonstrate significant improvement of LUTS. It can be performed reliably as a day case procedure. Longer term follow-up is required and will include the comparison of outcomes to standard BPH treatments.

    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings